Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease
Summary
The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.
What changed
The USPTO published patent application US20260097024A1, covering compositions and methods for treating metabolic syndrome, type 2 diabetes, obesity, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. The application includes method claims for treating these conditions and composition claims for the therapeutic combination.
For pharmaceutical companies and investors, the publication provides notice of potential future patent claims that could affect development of similar therapeutic compositions. The application remains pending, and the final scope of any granted claims may differ from the published application. Competitors should monitor prosecution and consider design-around strategies.
What to do next
- Monitor patent application prosecution for scope changes
- Review claims for potential infringement concerns
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS FOR AND METHODS TO TREAT, PREVENT, OR REVERSE METABOLIC SYNDROME, TYPE 2 DIABETES, AND/OR CARDIOVASCULAR DISEASE
Application US20260097024A1 Kind: A1 Apr 09, 2026
Inventors
Roger Catarino, William Kuhne
Abstract
The invention provides methods and compositions for treating, preventing, reducing the severity of, and/or reversing one or more of obesity, metabolic syndrome, and/or one or more comorbidities thereof. The compositions described herein comprise plant-based DHA and berberine in synergistically effective amounts.
CPC Classifications
A61K 31/4375 A61K 31/202 A61P 3/04
Filing Date
2025-10-07
Application No.
19352374
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.